All News

Use of testosterone replacement therapy more than tripled between 2003 and 2012 in a population of reproductive-age men, according to a study presented at the AUA annual meeting in New Orleans.

Higher radiation doses don’t confer a survival benefit in men with low-risk prostate cancer, although they do increase survival rates for men with medium- and high-risk cancers, the authors of a new study report.

While there is no benefit from using tamsulosin (Flomax) versus placebo for the treatment of small ureteral stones, there is a potential upside of increased passage from using the drug to treat 5- to 10-mm stones, according to a study from Australia published online in the Annals of Emergency Medicine (July 13, 2015).

With several years now passing since the USPSTF issued its grade D recommendation discouraging PSA-based prostate cancer screening, researchers are reporting conflicting findings on its impact on clinical practice.

The Independent Payment Review Board appears to be headed out of existence, much to the pleasure of much of the provider community-including urologists.

In this column, Ray Painter, MD, and Mark Painter also answer questions about coding for bladder hydrodistention under moderate sedation and re-positioning of a ureteral stent by a radiologist.

The Affordable Care Act has survived its latest legal challenge. After reading the Supreme Court's recent decision in King v. Burwell, Dan Shaffer of the AACU discusses how the justices arrived at it and what it means to you.

Active surveillance for men with low-risk prostate cancer has made it to prime time. That was the message of Stacy Loeb, MD, who moderated a press conference at the AUA annual meeting, where four studies documented the increasing popularity and safety of active surveillance in managing low-risk disease.